DEFA14A: OptiNose and Paratek Integration Progresses, Merger Closing Expected Around May 21, 2025

OptiNose and Paratek provide an update on integration planning following their executive leadership meeting, anticipating the merger to close around May 21, 2025, pending shareholder approval and regulatory clearances.

Summary

• OptiNose and Paratek Pharmaceuticals are progressing with their merger integration plans.
• Executive leadership teams from both companies met to review integration planning and alignment.
• The shareholder meeting to vote on the merger is scheduled for May 16, 2025.
• The companies anticipate closing the transaction around May 21, 2025, subject to customary closing conditions.
• These conditions include approval by OptiNose shareholders and receipt of necessary regulatory clearances.
• Integration planning is focused on maintaining stability and continuity throughout the transition.
• Beyond certain transitions at the Executive Team level, no immediate changes impacting OptiNose business operations or day-to-day roles are anticipated at the close of the transaction.
• Both companies continue to operate as separate organizations in the pre-close phase.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook regarding the merger's progress and integration planning, with a focus on stability and continuity. However, it also acknowledges potential risks and uncertainties associated with the transaction, leading to a moderately positive sentiment.

Positives

• Integration planning is underway to support the organization and employees through the next phase.
• The focus is on maintaining stability and continuity during the transition.
• No immediate changes are expected to OptiNose's business operations or day-to-day roles post-merger, except for some executive transitions.

Negatives

• The merger is subject to shareholder approval and regulatory clearances, which introduces uncertainty.
• The announcement of the merger could have negative effects on the market price of OptiNose's common stock and its operating results.

Risks

• The proposed transaction may not be completed in a timely manner or at all, which may adversely affect the company's business and stock price.
• Failure to obtain necessary regulatory approvals or shareholder approval could prevent the merger.
• The occurrence of any event, change, or other circumstances could lead to the termination of the merger agreement.
• Disruption from the pending merger could make it more difficult to maintain business and operational relationships.
• The merger could divert management's attention from ongoing business operations.
• Significant transaction costs and unknown liabilities are associated with the merger.
• There is a risk of litigation, including shareholder litigation, and/or regulatory actions related to the merger.

Future Outlook

The companies anticipate closing the transaction around May 21, 2025, subject to customary closing conditions, including approval by OptiNose shareholders and receipt of the necessary regulatory clearances. Future updates will be shared as the integration process evolves.

Management Comments

• Randy Brenner (Paratek's Chief Development and Regulatory Officer and Integration Lead) expressed being deeply impressed by everyone's commitment to advancing care for those with chronic rhinosinusitis, and by the dedication it took to achieve regulatory success, label expansion, and commercial impact.
• Randy Brenner stated that thoughtful planning is underway to support the organization and employees through the next phase.
• Randy Brenner stated that at the close of the transaction, beyond certain transitions at the Executive Team level, they do not anticipate any immediate changes impacting Optinose business operations or day-to-day roles.

Industry Context

The merger reflects a trend of consolidation in the pharmaceutical industry, where companies seek to expand their product portfolios and achieve synergies through mergers and acquisitions.

Stakeholder Impact

• Shareholders will vote on the proposed merger.
• Employees are assured of stability and continuity during the transition, with no immediate changes expected to their roles.
• Customers can expect continued service and support.
• Vendors and service providers can expect ongoing business relationships.

Next Steps

• OptiNose shareholders will vote on the proposed merger on May 16, 2025.
• The companies will continue integration planning.
• The companies will seek necessary regulatory clearances.
• The companies will provide updates throughout the integration process.

Key Dates

Keywords

merger, OptiNose, Paratek, integration, shareholder approval, regulatory clearances, transaction, closing